Clinical Trials Logo

Fibrolamellar Carcinoma clinical trials

View clinical trials related to Fibrolamellar Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05603572 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

NLP-KAT-101 is a Phase 1/2a dose escalation and expansion study to investigate the safety, tolerability, PK, and preliminary efficacy of oral + intratumoral (IT) KAT in subjects with HCC.

NCT ID: NCT03533582 Active, not recruiting - Hepatoblastoma Clinical Trials

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Start date: May 24, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy may kill more tumor cells than one type of chemotherapy alone.